JOHNSON & JOHNSON (JNJ) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for JOHNSON & JOHNSON?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, JOHNSON & JOHNSON's filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
+0.81%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does JOHNSON & JOHNSON actually do?
Answer:
Johnson & Johnson operates as a global healthcare company, organized into two primary segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on therapeutic areas including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism, developing prescription medicines. The MedTech segment offers a broad portfolio of products for cardiovascular, orthopaedics, surgery, and vision care, supporting physicians and healthcare systems. The company conducts business in virtually all countries worldwide, with a significant portion of sales generated internationally. Johnson & Johnson is committed to innovation, investing heavily in research and development to address unmet healthcare needs and improve patient outcomes across its diverse product lines.
Question:
What are JOHNSON & JOHNSON's revenue drivers?
Answer:
Revenue is primarily driven by the sale of prescription medicines within the Innovative Medicine segment and a broad portfolio of medical devices and technologies within the MedTech segment. Key drivers include the success of flagship products in oncology and immunology, as well as growth in cardiovascular and surgical device markets.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required